✦ LIBER ✦

Phase I trail of droloxifene in patients with metastatic breast cancer

✍ Scribed by Aman U. Buzdar, Shu Kau, Gabriel N. Hortobagyi…

Book ID: 120777327
Publisher: Springer
Year: 1994
Tongue: English
Weight: 399 KB
Volume: 33
Category: Article
ISSN: 0344-5704
DOI: 10.1007/BF00685906

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Droloxifene, a new antiestrogen: Its rol

Droloxifene, a new antiestrogen: Its role in metastatic breast cancer

✍ Winrich Rauschning; Kathleen I. Pritchard 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 891 KB

Effect of droloxifene treatment in metas

Effect of droloxifene treatment in metastatic breast cancer on tumor markers

✍ V. Möbus; G.P. Breitbach; R. Kreienberg; G. Bastert; H.J. Staab 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 96 KB

Oral vinorelbine in combination with cap

Oral vinorelbine in combination with capecitabine: phase I study in patients with metastatic breast cancer

✍ F Nole; C Catania; G Sanna; E Munzone; L Corsetto; B Longerey; A Saindon; M Bran 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 154 KB

A Phase I Study of Ixabepilone in Combin

A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer

✍ Henri Roché; Elena De Benedictis; Ewa Cottura; Silvia Govi; Florence Dalenc; Alb 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 354 KB

Gemcitabine and epirubicin in patients w

Gemcitabine and epirubicin in patients with metastatic breast cancer: A phase I/II study

✍ Mario Campone; Pierre Fumoleau; Patrice Viens; Véronique Diéras; Eric Pujade-Lau 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Phase II study of ionidamine in patients

Phase II study of ionidamine in patients with metastatic breast cancer

✍ H. Ian Robins; Donna S. Neuberg; Al B. Benson; Kishan J. Pandya; Douglass C. Tor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 193 KB

The Eastern Cooperative Oncology Group conducted a phase II study of lonidamine in patients with metastatic breast cancer. The drug was given orally to a maximum daily dose of 340 mg/m 2. Forty-two patients were entered on study. One partial response was observed; there were no life-threatening toxi